News Release Details
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
- Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the
World Health Organizationdrinking risk levels1
- Trial is informed by results from Phase 1 studies that showed pharmacokinetic properties of OPNT002 well suited for ‘as needed’ administration, either in anticipation of drinking or once drinking has started2,3
- Target enrollment of approximately 300 patients; Results anticipated in 2023
- Alcohol Use Disorder is a chronic relapsing brain disease characterized by compulsive heavy drinking and is among the most prevalent mental health disorders globally4
“The development of OPNT002 is predicated on modifying a patient’s drinking behavior in order to reduce the harm of alcohol,” said
Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brain’s endogenous opioids. These endorphins are thought to activate opioid receptors, which contribute to alcohol’s reinforcing and addictive properties. Current naltrexone treatments work to block mu-opioid receptors when administered orally or through injection. However, converging lines of evidence indicate that activation of delta-opioid receptors also contributes to the reinforcing properties of alcohol. The effective blockade of delta‐opioid receptors requires much higher plasma naltrexone concentrations than is achieved by currently approved naltrexone products5.
Opiant is developing OPNT002 to rapidly increase plasma concentrations of the drug following dosing and thereby block mu and delta-opioid receptors. In previous research, OPNT002 has demonstrated rapid nasal absorption, delivering high levels of naltrexone yet with a short half-life. Results from Phase 1 studies demonstrate that OPNT002 produces maximum plasma concentrations that are approximately 50% higher than orally administered naltrexone. This feature, along with a very rapid onset and a short plasma half-life, are characteristics ideally suited to developing OPNT002 for ‘as needed’ nasal dosing in anticipation of drinking, or once drinking has started2,3. The primary end point will be the proportion of subjects showing an improvement in
The trial is a randomized, double-blind, placebo-controlled study that will enroll approximately 300 patients at sites within the
“Multiple medications are approved for the treatment of AUD, yet less than 10% of individuals with AUD currently receive treatment,” said
About Alcohol Use Disorder
Alcohol Use Disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake. It is the third leading preventable cause of death in
About Opiant Pharmaceuticals, Inc.
For more information visit: www.opiant.com.
This press release contains forward-looking statements, including the anticipated results of the Phase 2 study in 2023. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 4, 2021, including under the caption titled "Risk Factors." These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
For Media and Investor Inquiries:
1. Witkiewitz, K et al. Drinking Risk Level Reductions Associated with Improvements in
2. Krieter P, et al. Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose.
3. Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose. Available at: http://ir.opiant.com/events/event-details/research-development-meeting-emerging-therapeutics-treatment-addiction-and
4. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders.
5. Weerts E, Kim Y, Wand G, et al. Differences in δ and μ opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharm. 2008;33:653-665.
6. National Institute on Alcohol Abuse and Alcoholism. Available at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-use-disorders
7. World Health Organization. Available at: https://www.who.int/health-topics/alcohol#tab=tab_1
8. Spencer, M et al. Rates of Alcohol-induced Deaths Among Adults Aged 25 and Over in Urban and Rural Areas:
9. Pollard, M et al. Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. Jama Network doi: 10.1001/jamanetworkopen.2020.22942,
Source: Opiant Pharmaceuticals, Inc.